Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The profitability metrics demonstrate a shifting performance landscape over the five-year period. While gross profit margin remains consistently high, operating and net profit margins, as well as returns on equity and assets, exhibit a clear downward trajectory followed by a period of stabilization.
- Gross Profit Margin
- The gross profit margin is consistently strong, beginning at 84.83% in 2021 and decreasing gradually to 85.35% in 2025. This suggests a sustained ability to manage production costs relative to revenue. The fluctuations are relatively minor, indicating a stable core business profitability.
- Operating and Net Profit Margins
- A significant decline is observed in both operating and net profit margins. The operating profit margin decreased substantially from 55.67% in 2021 to 24.95% in 2025. Similarly, the net profit margin fell from 50.25% to 31.41% over the same period. While the rate of decline slows in the later years, the overall trend indicates increasing operational and post-tax expenses relative to revenue. A slight increase in net profit margin is noted between 2023 and 2025, potentially signaling a stabilization of these margins.
- Return on Equity (ROE)
- Return on equity experienced a pronounced decrease, moving from 43.03% in 2021 to 14.41% in 2025. This indicates a diminishing ability to generate profit from shareholder investments. The decline mirrors the trend in net profit margin, suggesting that lower profitability is directly impacting returns to equity holders. The rate of decrease slows considerably between 2023 and 2025.
- Return on Assets (ROA)
- Return on assets followed a similar pattern to ROE, decreasing from 31.75% in 2021 to 11.11% in 2025. This suggests a reduced efficiency in utilizing assets to generate earnings. The trend aligns with the observed declines in operating and net profit margins, indicating that the company is generating less profit per dollar of assets. The rate of decline also slows between 2023 and 2025.
In summary, while the company maintains a strong gross profit margin, its ability to translate that into operating and net profit, and subsequently returns for investors and efficient asset utilization, has diminished over the observed period. The stabilization observed in the most recent years suggests a potential leveling off of these negative trends, but continued monitoring is warranted.
Return on Sales
Return on Investment
Gross Profit Margin
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Gross profit | ||||||
| Revenues | ||||||
| Profitability Ratio | ||||||
| Gross profit margin1 | ||||||
| Benchmarks | ||||||
| Gross Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
The gross profit margin exhibited relative stability over the five-year period, fluctuating within a narrow range. While gross profit and revenues both experienced declines from 2021 to 2022, the gross profit margin itself increased during that same period. Subsequent years show increases in both gross profit and revenues, with the gross profit margin remaining consistently high, before experiencing a slight decline in the most recent year.
- Gross Profit Margin Trend
- The gross profit margin began at 84.83% in 2021. It increased to 87.18% in 2022, representing the highest value observed during the period. The margin then decreased slightly to 86.16% in 2023 and remained relatively stable at 86.13% in 2024. A modest decrease to 85.35% was observed in 2025.
- Relationship to Revenue and Gross Profit
- From 2021 to 2022, both revenues and gross profit decreased. However, the decrease in gross profit was proportionally smaller than the decrease in revenues, resulting in an increased gross profit margin. From 2022 to 2024, both revenues and gross profit increased, and the gross profit margin remained relatively consistent. The slight decrease in the gross profit margin in 2025 occurred alongside a smaller percentage increase in gross profit compared to the increase in revenues.
Overall, the company demonstrates a strong ability to maintain profitability at the gross level. The observed fluctuations suggest a sensitivity to changes in revenue, but the consistently high margins indicate effective cost management or pricing strategies. The slight decline in the most recent year warrants further investigation to determine if it represents a developing trend or a temporary anomaly.
Operating Profit Margin
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Income from operations | ||||||
| Revenues | ||||||
| Profitability Ratio | ||||||
| Operating profit margin1 | ||||||
| Benchmarks | ||||||
| Operating Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Operating Profit Margin, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Operating Profit Margin, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Operating profit margin = 100 × Income from operations ÷ Revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
The operating profit margin demonstrates a consistent decline over the five-year period. While initially strong, profitability has eroded progressively from 2021 to 2025. This trend is coupled with fluctuations in both income from operations and revenues, which contribute to the observed margin compression.
- Operating Profit Margin Trend
- The operating profit margin began at 55.67% in 2021. A substantial decrease to 38.93% was recorded in 2022, followed by further reductions to 30.85% in 2023, 28.10% in 2024, and finally reaching 24.95% in 2025. This represents a cumulative decline of approximately 30.72 percentage points over the observed timeframe.
- Income from Operations
- Income from operations decreased significantly from US$8,946,800 thousand in 2021 to US$4,738,900 thousand in 2022. Subsequent years show a more moderate decline, moving from US$4,047,100 thousand in 2023 to US$3,990,700 thousand in 2024, and finally to US$3,577,900 thousand in 2025. The largest single-year decrease occurred between 2021 and 2022.
- Revenue Trend
- Revenues experienced a decrease from US$16,071,700 thousand in 2021 to US$12,172,900 thousand in 2022. Revenues then increased in 2023 to US$13,117,200 thousand, and continued to rise to US$14,202,000 thousand in 2024, and US$14,342,900 thousand in 2025. While revenues recovered somewhat after the initial decline, the growth was insufficient to offset the decline in income from operations and halt the erosion of the operating profit margin.
The consistent decrease in the operating profit margin, despite revenue recovery in later years, suggests increasing operational costs or pricing pressures are impacting profitability. Further investigation into the components of cost of goods sold and operating expenses would be necessary to determine the primary drivers of this trend.
Net Profit Margin
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income | ||||||
| Revenues | ||||||
| Profitability Ratio | ||||||
| Net profit margin1 | ||||||
| Benchmarks | ||||||
| Net Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Net Profit Margin, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Net Profit Margin, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Net profit margin = 100 × Net income ÷ Revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
The net profit margin exhibited a declining trend from 2021 to 2023, followed by a period of stabilization and slight improvement through 2025. While net income and revenues both experienced fluctuations during the period, the net profit margin provides a crucial perspective on the company’s profitability relative to its sales.
- Overall Trend
- The net profit margin decreased significantly from 50.25% in 2021 to 30.14% in 2023. This represents a substantial reduction in profitability. However, the margin then showed signs of recovery, increasing to 31.07% in 2024 and further to 31.41% in 2025, indicating a potential stabilization of profitability.
- Net Income and Revenue Relationship
- In 2022, both net income and revenues decreased considerably compared to 2021. This contributed to the initial decline in the net profit margin. While revenues increased in both 2023 and 2024, the growth in net income was more modest, resulting in a continued, albeit slower, decrease in the margin in 2023. The slight increase in net income relative to revenue growth in 2024 and 2025 drove the observed margin improvement.
- Magnitude of Change
- The largest single-year decrease in net profit margin occurred between 2021 and 2022, with a drop of 14.61 percentage points. The subsequent decrease from 2022 to 2023 was 5.50 percentage points. The increases from 2023 to 2024 and 2024 to 2025 were relatively small, at 0.93 and 0.34 percentage points respectively, suggesting that the company’s efforts to improve profitability are yielding incremental results.
The stabilization of the net profit margin in the later years of the period suggests that the company may be successfully managing its costs or pricing strategies following the initial decline. Further investigation into the underlying drivers of revenue and expense changes would be necessary to fully understand these trends.
Return on Equity (ROE)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income | ||||||
| Stockholders’ equity | ||||||
| Profitability Ratio | ||||||
| ROE1 | ||||||
| Benchmarks | ||||||
| ROE, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| ROE, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| ROE, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
ROE = 100 × Net income ÷ Stockholders’ equity
= 100 × ÷ =
2 Click competitor name to see calculations.
The Return on Equity (ROE) demonstrates a significant decline over the five-year period, coupled with fluctuations in both net income and stockholders’ equity. Initial values are strong, but subsequent years reveal a decreasing trend in ROE, despite increasing stockholders’ equity.
- Net Income Trend
- Net income began at US$8,075,300 thousand in 2021, then decreased substantially to US$4,338,400 thousand in 2022. It continued to decline to US$3,953,600 thousand in 2023, before experiencing modest increases to US$4,412,600 thousand in 2024 and US$4,504,900 thousand in 2025. While income shows a slight recovery in the latter two years, it does not return to the levels observed in 2021.
- Stockholders’ Equity Trend
- Stockholders’ equity consistently increased throughout the period. Starting at US$18,768,800 thousand in 2021, it rose to US$22,664,000 thousand in 2022, US$25,973,100 thousand in 2023, US$29,353,600 thousand in 2024, and finally reached US$31,256,900 thousand in 2025. This consistent growth in equity contrasts with the fluctuating net income.
- ROE Analysis
- ROE began at a high of 43.03% in 2021. A substantial decrease was observed in 2022, falling to 19.14%. This downward trend continued, with ROE reaching 15.22% in 2023, 15.03% in 2024, and further declining to 14.41% in 2025. The decline in ROE, despite the growth in stockholders’ equity, suggests that the company is becoming less efficient at generating profits from shareholder investments. The initial drop in 2022 is likely attributable to the significant decrease in net income, while the continued decline in subsequent years indicates that net income increases are not keeping pace with the growth in equity.
The combination of fluctuating net income and consistently increasing stockholders’ equity results in a pronounced and sustained decrease in ROE. This trend warrants further investigation to determine the underlying causes and potential implications for future profitability.
Return on Assets (ROA)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income | ||||||
| Total assets | ||||||
| Profitability Ratio | ||||||
| ROA1 | ||||||
| Benchmarks | ||||||
| ROA, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| ROA, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| ROA, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
ROA = 100 × Net income ÷ Total assets
= 100 × ÷ =
2 Click competitor name to see calculations.
The Return on Assets (ROA) exhibited a significant decline over the observed period, followed by a period of relative stabilization. Net income fluctuated, while total assets consistently increased year-over-year. This combination drove the observed changes in ROA.
- Overall Trend
- A substantial downward trend in ROA is evident from 2021 to 2023. The ratio decreased from 31.75% in 2021 to 11.95% in 2023. The rate of decline slowed between 2023 and 2025, with ROA stabilizing around the 11% to 12% range.
- Net Income Impact
- Net income decreased considerably from 2021 to 2022, falling from US$8,075,300 thousand to US$4,338,400 thousand. While net income experienced further reduction in 2023, it showed modest growth in 2024 and 2025, reaching US$4,504,900 thousand. This suggests that while net income initially contributed to the ROA decline, its subsequent stabilization helped to limit further decreases in the ratio.
- Asset Growth Impact
- Total assets increased consistently throughout the period, rising from US$25,434,800 thousand in 2021 to US$40,558,700 thousand in 2025. This continuous asset growth, coupled with the initial decline in net income, likely exerted downward pressure on ROA. The increasing asset base required a higher level of net income to maintain the same ROA percentage.
- Recent Performance
- From 2023 to 2025, ROA remained relatively stable, fluctuating between 11.11% and 11.95%. This suggests that the factors impacting ROA – net income and asset levels – reached a new equilibrium during this period. The slight variations within this range indicate ongoing, but limited, changes in the relationship between profitability and asset utilization.